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Abstract
Background: Hepatitis C virus (HCV) is common in men who have sex with men (MSM) with HIV. The Swiss HCVree
Trial targeted a micro-elimination by using a treat and counsel strategy. Self-reported condomless anal intercourse with
non-steady partners was used as the selection criterion for participation in a counselling intervention designed to
prevent HCV re-infection. The purpose of this study was to assess the ability of this criterion to identify men who
engaged in other sexual risk behaviours associated with HCV re-infection.
Methods: Men who disclosed their sexual and drug- use behaviours during the prior 6 months, at study baseline,
were included in the current study. Using a descriptive comparative study design, we explored self-reported sexual and
drug-use risk behaviours, compared the odds of reporting each behaviour in men who reported and denied
condomless anal intercourse with non-steady partners during the prior year and calculated the sensitivity/
specificity (95% CI) of the screening question in relation to the other at-risk behaviours.
Results: Seventy-two (61%) of the 118 men meeting eligibity criteria reported condomless anal intercourse
with non-steady partners during the prior year. Many also engaged in other potential HCV transmission risk
behaviours, e.g., 52 (44%) had used drugs. In participants disclosing drug use, 44 (37%) reported sexualised
drug use and 17 (14%) injected drugs. Unadjusted odds ratios (95% CI) for two well-known risk behaviours
were 2.02 (0.80, 5.62) for fisting and 5.66 (1.49, 37.12) for injecting drug use. The odds ratio for sexualised drug use - a
potential mediator for increased sexual risk taking - was 5.90 (2.44, 16.05). Condomless anal intercourse with non-steady
partners showed varying sensitivity in relation to the other risk behaviours examined (66.7–88.2%).
Conclusions: Although condomless anal intercourse with non-steady partners was fairly sensitive in detecting other
HCV relevant risk behaviours, using it as the only screening criterion could lead to missing a proportion of HIV-positive
men at risk for HCV re-infection due to other behaviours. This work also points to the importance of providing access
to behavioral interventions addressing other sexual and drug use practices as part of HCV treatment.
Trial registration: Clinical Trial Number: NCT02785666, 30.05.2016.
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Background
In men who have sex with men (MSM) living with HIV,
co-infection with hepatitis C virus (HCV) has become a
concern over the last 20 years [1]. An HCV RNA-
screening of MSM with HIV (n = 3722) participating in
the Swiss HIV Cohort Study (SHCS) between October
2015 and May 2016 showed a prevalence of 4.8% (n =
177) [2]. People living with an HIV/HCV co-infection
show faster progression of liver fibrosis compared to
people with HCV mono-infection and higher risk for
liver-related morbidity and mortality [3]. Since the intro-
duction of the new direct acting antivirals (DAAs) cure
is possible in 95% of the cases, making micro-
elimination of HCV a realistic target [4]. However, the
population of MSM with HIV frequently present with
HCV (re-) infections and current evidence shows that
sexual transmission is one important source of (re-) in-
fection [5]. Addressing sexual risk behaviour should
become an essential component of HCV medical treat-
ment [6].
In MSM, several sexual behaviours have been de-
scribed as potentially risky, for example mucosally trau-
matic sexual behaviours including condomless anal
intercourse (CAI), receptive fisting, rectal bleeding, anal
douching, sharing of sex toys and group sex activities;
nasally applied drugs; injection drug use and drug use in
combination with sex [7–9]. Still, to-date, it remains
controversial which risk behaviours are the most import-
ant ones regarding HCV transmission in MSM with
HIV, and should subsequently constitute the most im-
portant targets for preventive efforts [10].
From 2015 to 2017, the Swiss HCVree Trial was con-
ducted as an investigator-initiated substudy of the SHCS
using a test, treat and counsel strategy with the goal to
eliminate HCV in the MSM population with HIV [11].
An E-health assisted behavioural counselling interven-
tion with nurses as counselors was developed and imple-
mented with the aim to reduce sexual risk taking. MSM
co-infected with HIV/HCV were asked to participate in
the counseling intervention if they reported condomless
anal intercourse with non-steady partners (nsCAI) the
year prior to starting treatment [11]. Condomless anal
intercourse was the only risk behaviour for which SHCS
data was available [12] at the time of intervention devel-
opment. However, its usefulness in selecting participants
for the additional sexual risk reduction intervention re-
mains questionable given that other sexual and drug-
using behaviours are also important risk factors for HCV
transmission. The current analysis was conducted to
investigate the usefulness of nsCAI as the selection cri-
terion for the behavioural intervention. This can provide
important information for further studies. Specifically,
the aims of this study were to (1) describe sexual and
drug-using behaviours participants reported during Swiss
HCVree study baseline assessment and to compare those
behaviours in MSM who did and did not report nsCAI
during the prior year and to (2) examine the condom-use
question’s sensitivity and specificity in identifying men
who engaged in other HCV relevant risk behaviours and
who may, therefore, also benefit from risk reduction
interventions.
Methods
A descriptive comparative study design was used to
address the objectives and included a comprehensive as-
sessment of social, medical and behavioural factors. Data
were compared for differences between the two groups:
those who reported nsCAI and those who denied nsCAI
during the prior year.
Setting and participants
The Swiss HCVree Trial was implemented within the
framework of the SHCS, an ongoing multicentre
prospective observational study that started in 1988. Its
participants have been shown to be highly representative
of all known people living with HIV (PLWH) in
Switzerland, [13] and modelling studies estimate that
84% of all MSM with HIV in Switzerland are followed in
the SHCS [14]. During the Swiss HCVree Trial (2015–
2017), all adult men with self-identified homosexual or
bisexual preferences enrolled in the SHCS (n = 3722)
were assessed for HCV ribonucleic acid (RNA) [2]. One
hundered twenty-two (122) were diagnosed with HCV
and treated with DAAs in one of eight specialized HIV
clinics in Switzerland [11] and all but one individual
were cured. Among the men treated with DAAs, a posi-
tive response to the nsCAI question in the SHCS during
the prior year was used to select men who were invited
to participate in the sexual risk reduction intervention
performed by nurses.
Data collection
The data used in this analysis were retrieved from the
SHCS database and the Swiss HCVree Trial baseline
assessment. Data included sociodemographic character-
istics (age, ethnicity/race, highest completed educational
degree) and medical information about HIV from the
SHCS database and HCV specific information from the
Swiss HCVree Trial. At Swiss HCVree Trial baseline,
participants were asked to complete a self-reported
questionnaire about sexual and drug-use behaviours dur-
ing the previous 6 months. Table 1 summarizes the data
collected.
Data analysis
Analyses were conducted using the open source R statis-
tical analysis software (Version 1.0.136 for Mac OS X).
Participants’ characteristics and self-reported at-risk
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sexual and drug-use behaviours were analysed descrip-
tively. Depending on the level of measurement and dis-
tribution of variables, frequencies, percentages, means
and standard deviations (SD), or median and interquar-
tile range (IQR) were calculated. Based on the SHCS
data, participants were divided into two groups: those
who reported no sex with non-steady partners or only
protected anal intercourse during all sexual encounters
during the last 12 months (i.e. without nsCAI) and those
reporting nsCAI. Baseline characteristics, attitudes and
self-efficacy regarding condom use were compared in
the two nsCAI groups. Chi-square tests were used to
compare categorical variables and the student’s t-test
(for age, which was normally distributed) or Mann-
Whitney U tests (for years since HIV diagnosis and
scores on the attitudes toward condom use and self-
efficacy questionnaires, which were not normally distrib-
uted) were utilised to compare continuous variables.
Odds ratios and their 95% confidence intervals (CI) were
calculated to examine the association between nsCAI
and the other risk behaviours assessed. Multivariable
logistic regression was conducted to determine if adjust-
ing for age and duration of HCV affected the relation-
ship between nsCAI and the other risk behaviors. We
used a manual stepwise backward elimination. MedCalc
online software (https://www.medcalc.org/calc/diagnostic_
test.php) was used to calculate the sensitivity and specificity
(including 95% CI) of the condom use screening question
with non-steady sexual partners in relation to the
other at-risk sexual and drug use behaviours.
Results
During the Swiss HCVree Trial baseline assessment, 118
of 122 participants disclosed their sexual and drug-use
behaviours and were included in the current study, see
Fig. 1.
Based on SHCS data, 72 (61%) MSM reported nsCAI
and 46 (39%) reported no nsCAI during the 12months
prior to enrollment in the Swiss HCVree Trial. There
were no significant differences in the two groups’ socio-
demographic characteristics. There were significant group
differences in the years since HCV diagnosis; MSM with
Table 1 Data collected
Database Domain Variables assessed Question Answer
SHCS, reported in
interview situation
Screening question
Selection criteria for sexual
risk reduction intervention
“Over the last 12 months, did you have
unprotected anal intercourse with occasional
partners?”
Yes/no
Swiss HCVree Trial, Self-
completed
questionnaires
Sociodemographic
Partnership “Did you have a stable partnership in the last 6
months?”
Yes/no
Risk Behaviours
Sextoys “Over the last 6 months, did you use sextoys with
non-steady partners?”
Yes/no
Fisting “Over the last 6 months, did you practice fisting?” Yes/no
Drug use “Did you use one or more of the following
substances in the last 6 months?”
Cocaine Yes/no
γ-butyrolactone/γ-hydroxybutyric acid (GHB/GBL) Yes/no
crystal methamphetamine (CM) Yes/no
ketamine Yes/no
mephedrone Yes/no
“If your answer is yes, how did you take the
substance(s)?”
injection (slammed)/ intranasal/orally/
smoked/ mucosally (anal)
Sexualised drug use “If your answer is yes, did you take any of the
above-mentioned substance(s) in combination
with sex?”
Yes/no
Psychological constructs
Attitudes towards
condom use
Sexual risks scale-attitudes toward condom use
[15] 13 items rated on a 5-point Likert scale
1 (I don’t agree at all) to 5 (I completely
agree). Possible scores range from 13 to
65
Condom self-efficacy Self-efficacy for negotiating condom use [16], 5
items rated on a 1–10 scale
0 (I cannot) to 10 (I am sure that I can).
Possible scores range from 0 to 50
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nsCAI had a shorter median duration of 1.9 years (0.9–
5.1) compared to MSM without nsCAI with a median
duration of 4.8 years (2.1–10.3). Participants without
nsCAI scored significantly more positive attitudes toward
condom use and had higher self-efficacy related to con-
dom use than men with nsCAI (median score = 44.00 vs.
39.00, p = .023 and median score = 40.72 vs. 29.23, p < .001
respectively).
Many men reported engaging in a variety of sexual
or drug-use behaviours identified as risk factors for
HCV-infection: 25 (24%) shared sextoys, 28 (25%)
practised fisting and 52 (44%) used drugs during the
prior 6 months. In participants who answered the
drug-use questions, 44 (37%) reported sexualised drug
use and 17 (15%) injected drugs. Participants reported
using the following drugs: 30 (26%) used γ-
butyrolactone/γ-hydroxybutyric acid (GHB/GBL), 26
(22%) cocaine, 22 (19%) crystal methamphetamine, 11
(9%) ketamine and 10 (9%) mephedrone (Table 2).
Those with nsCAI during the 12 months prior to
treatment were more likely to have engaged in other
risky sexual behaviours than those without nsCAI al-
though the odds in the two groups were only statisti-
cally significant for drug use, drug use during sex and
injecting drugs. Adjusting for age and/or HCV dur-
ation did not change the relationship between nsCAI
and the other risk behaviours examined in terms of
the direction or significance of the odds ratios.
Odds ratios for two sexual behaviours with established
transmission risk were 2.02 (0.80, 5.62) for fisting and
5.66 (1.49, 37.12) for injecting drug use. Sexualised drug
use, a potential mediator for increasing other risk behav-
iours, showed an odds ratio of 5.90 (2.44, 16.05), see
Table 2.
Table 3 summarizes the results of analyses examining
the sensitivity and specificity of reporting consistent
condom-use with non-steady partners at study baseline
in identifying men who did not engage in the other at-
risk behaviours examined. The nsCAI question had the
highest sensitivity in relation to the question about
injecting drugs (88.2%) and lowest for sharing sex toys
(66.67%). Specificity was low in all analysed risk behav-
iours (41.18–57.58%).
Discussion
The MSM co-infected with HIV/HCV in this study prac-
ticed various sexual and drug use behaviours associated
with HCV transmission risk in addition to condomless
sex. While nsCAI was associated with higher odds of
engaging in other behaviours, based on our findings,
relying only on this question to identify men at risk for
HCV re-infection is likely miss a proportion of MSM
Fig. 1 Flowchart Swiss HCVree Trial and group building according to men’s response to the nsCAI screening question
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with HIV at risk for HCV due to other behaviours.
Between 16 to 18% of the men who denied nsCAI
reported engaging in other behaviors that have been
associated with an increased risk of HCV re-infection.
Eighteen percent (18%) of those who denied nsCAI
reported using drugs. This is an important finding as
drug use is seen as a potential mediator for increased
sexual risk-taking [17, 18].
Condom use was the only risk behaviour available for
all men in the SHCS and was for this reason used as the
criterion for selecting men to participate in the sexual
risk reduction behavioural intervention portion of the
Swiss HCVree Trial [19]. Despite our use of this inclu-
sion criterion, its discriminatory value in identifying men
at high risk for HCV re-infection was unclear. However,
a recent study from London found that CAI was a
significant risk factor for acute HCV infection in MSM
and in one third of participants it was the only risk
factor [9]. In contrast to our study, MSM received care
in a sexual health clinic and benefitted from a multi-
disciplinary prevention approach including harm reduc-
tion services whereas in our study, HCV treatment was
given in specialised medical HIV clinics. In line with
other investigations in MSM with HIV, study partici-
pants reported various behaviours other than nsCAI that
potentially increased their risk of HCV sexual transmis-
sion [9]. It has been well documented that condoms are
less attractive in the MSM community – largely due to
the common understanding and awareness that HIV
treatment is preventive in terms of HIV transmission
[20]. Decreasing trends of condom use was confirmed in
a systematic review of studies across high-income coun-
tries [21]. Champenois et al. [22] reported that for MSM
with HIV the main reasons for not using condoms were
serosorting and being on antiretroviral therapy (ART)
with undetectable viral loads. While these traditional
HIV-related risk reduction strategies (serosorting and
Table 2 Sociodemographic and HCV-related risk behaviours in the last 6 months at study baseline
Sociodemographic and
HCV-related risk behaviours
at study baseline
Total
(n = 118)
Participants
without nsCAI
(n = 46)
Participants with nsCAI
(n = 72)
Univariable Odds Ratio
(95% CI)
Multivariable Adjusted
OR (95% CI) for age
and HCV duration
Adjusted OR
(95% CI) for
HCV duration
Age, mean (sd) 46.6 (+/−
9.2)
49.0 (+/− 9.1) 45.1 (+/− 9.1) 0.64 (0.41, 0.96)a
HCV duration, median
(IQR)
2.9 (1.1–
7.1)
4.8 (2.1–10.3) 1.9 (0.9–5.1) 0.87 (0.80, 0.94)
Sharing sextoys, n (%)
(n = 104/38/66)b
25 (24) 7 (18) 18 (28) 1.53 (0.58, 4.40) 1.05 (0.36, 3.21) 1.08 (0.37,
3.29)
Fisting, n (%) (n = 114/
43/71)b
28 (25) 7 (16) 21 (30) 2.02 (0.80, 5.62) 2.12 (0.78, 6.31) 1.92 (0.72,
5.60)
Drug use, n (%) (n = 117/
45/72)b
52 (44) 8 (18) 44 (61) 7.27 (3.08, 18.91) 5.58 (2.26, 15.02) 5.79 (2.37,
15.42)
GHB/GBL, n (%) 30 (26) 3 (7) 27 (38) 8.60 (2.78, 37.87) 6.64 (2.04, 30.18) 6.91 (2.15,
31.07)
Cocaine, n (%) 26 (22) 6 (13) 20 (28) 2.56 (0.99, 7.55) 2.36 (0.85, 7.39) 2.49 (0.91, 7.6)
Crystal methamphetamine,
n %)
22 (19) 1 (2) 21 (29) 18.48 (3.63, 338.0) 15.47 (2.89, 288.31) 15.91 (3.01,
294.78)
Ketamine, n (%) 11 (9) 2 (4) 9 (14) 3.12 (0.76, 21.14) 3.55 (7.82, 25.71) 3.55 (7.82,
25.71)
Mephedrone, n (%) 10 (9) – 10 (15)
Use of any of the drugs
listed above during sex, n
(%) (n = 116/45/71)b
44 (38) 7 (16) 37 (52) 5.90 (2.44, 16.05) 4.42 (1.73, 12.52) 4.63 (1.84,
12.92)
Reporting injection of
drugs, n (%) (n = 117/45/72)b
17 (15) 2 (4) 15 (21) 5.66 (1.49, 37.12) 4.45 (1.10, 30.15) 4.53 (1.13,
30.51)
aUnit 10 years
bspecified how many HIV-positive MSM answered the question (n = total group/without nsCAI/with nsCAI)
Table 3 Sensitivity analysis of screening question “nsCAI” to
identify other probable risk behaviours for HCV re-infection
Risk Behaviours Sensitivitya (%) (95% CI) Specificityb (%) (95% CI)
Any drug use 84.62 (71.92–93.12) 57.58 (44.79–69.66)
Sexualised drug use 84.09 (69.93–93.36) 52.70 (40.75–64.43)
Injecting drug use 88.24 (63.56–98.54) 43.56 (33.72–53.80)
Fisting 75.00 (55.13–89.31) 43.18 (32.66–54.18)
Sharing of sex toys 66.67 (48.17–82.04) 41.18 (30.61–52.38)
aThe probability that HIV-positive MSM report a selected risk behaviour will
also report nsCAI
bThe probability that HIV-positive MSM will deny nsCAI if they are not
engaging in other selected other risk behaviours
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effective HIV treatment) have been shown to prevent
the transmission of HIV, they have little or no effect in
preventing HCV or other sexually transmitted diseases.
In our study, MSM with HIV and nsCAI were more
likely to engage in other risk behaviours compared to
those without nsCAI but the relationship was only statis-
tically significant for drug-use and sexualized drug-use.
However, due to the small sample size, our study was
probably only adequately powered to detect large differ-
ences in the groups. They were two-times more likely to
practice fisting and six times more likely to report sexua-
lised drug use. The sensitivity of the nsCAI question was
85% in relation to drug use. Nevertheless, our findings
indicate that using nsCAI as the only risk behaviour
criterion to select men for the behavioural intervention
was likely to have resulted in failure to include between
12 and 34% of those engaging in other risk behaviours.
Each single behaviour included in the current analysis
carries a specific HCV transmission risk; however, which
behaviour or combinations of behaviours carry the high-
est risks is currently less clear and cannot be answered
with this study design.
Our results are in line with other studies showing as-
sociations between higher rates of drug use/sexualised
drug use and risk behaviors [18, 23, 24]. A substantial
proportion of our participants reported drug use (44%).
Among the men who answered these questions (116 for
sexualized drug use and 117 for injecting drugs), 38%
reported sexualised drug use and 15% reported injecting
substances. In comparison, in two earlier studies on
MSM with HIV– one from Madrid (n = 742) [23] and
one from England/Wales (n = 392) [24]– 29.1–29.5% of
participants indicated sexualised drug use and 10.1–16%
injecting drug use. Our group’s higher rate of sexualised
drug use might reflect differences in the study popula-
tion, especially the fact that our sample’s MSM with
HIV were all co-infected with HCV. Several studies have
found elevated rates of sexualised drug use in MSM co-
infected with HIV/HCV, affirming associations between
sexual HCV transmission and higher risk taking behav-
iours when using substances [25, 26]. Another possible
explanation for our group’s high rates of sexualised drug
use may be related to the study setting: most of our par-
ticipants were recruited at the centres in Zurich, a town
known for a comparably high prevalence of sexualised
drug use. In the European MSM Internet Survey (EMIS-
2010), which compared 44 European cities in relation to
illicit drug use in MSM, place of residence was the
strongest predictor. Zurich reported a 7% prevalence of
using one of the four drugs typically used during sex,
ranking sixth of the 44 cities studied, just after UK and
Spanish cities [8]. In another European survey conducted
among MSM in 13 cities, overall prevalence of sex asso-
ciated with drug use was 11.8% (when measured at the
last sexual encounter), and was more frequently reported
by MSM with HIV [27].
The four substances typically used during sex were all
reported in our study, with GBL/GHB being the most
common (25%), followed by crystal methamphetamine
(19%). In EMIS (European MSM Internet Survey), per-
centages of GBL/GHB use were quite similar, but crystal
methamphetamine use was lower [8] than in our study,
suggesting a surge in its popularity in MSM with HIV.
The frequency of cocaine use was also high (22%) –
comparable to rates reported in the UK ASTRA trial in
MSM with HIV or for Zurich in EMIS [8, 18]. To date,
few studies investigating sexualized drug use have in-
cluded cocaine. However, our results indicate that cocaine
may be more common (19%) in sexual contexts than
expected.
This study has several limitations. The study’s cross-
sectional design precluded any causal inferences about
the associations between nsCAI and other behaviours
risky for HCV re-infection. During analysis, we identified
some limitations in the formulation of questions, e.g., we
did not ask about the distinction between insertive or re-
ceptive fisting. While self-report questionnaire data may
be biased, especially for such sensitive domains as sexual
and drug use behaviour, it is often perceived as superior
compared to being asked by someone else because of
reduced social desirability bias [28]. Given the limited
number of MSM co-infected with HIV/HCV in
Switzerland, the study sample (118 participants) was
small. The small sample size may have limited our ability
to detect statistically significant differences in behaviors
in the nsCAI and non-nsCAI groups that were clinically
meaningful. One strength of the study is that Swiss
HCVree Trial (the source of data for this study)
screened and treated all participants co-infected with
HCV in the SHCS, so the sample is likely to be represen-
tative of MSM with HIV living in Switzerland [13].
Conclusions
Our findings support existing research that MSM co-
infected with HIV/HCV engage in various sexual and
drug-use behaviours, potentially increasing their risk of
HCV re-infection. Men who reported using condoms
inconsistently with non-steady partners were more likely
to report engaging in the other sexual and drug-use
behaviors measured although the differences were only
statistically significant for the drug-use behaviors. nsCAI
was fairly sensitive in identifying men who also engaged
in other risk behaviours, but relying only on it to identify
men at risk for HCV infection would miss a proportion
of MSM with HIV practicing other potentially modifi-
able behaviours. Based on our findings we recommend
comprehensive screening of potential risk behaviours to
identify men whose sexual and drug use behaviors
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increase their risk for HCV infection. We recommend
offering all MSM co-infected with HIV/HCV behav-
ioural interventions designed to reduce sexual and drug
use risk behaviours.
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